In a world where bacterial infections kill 10 million people annually, Resistell is betting that speed is the ultimate weapon. Their pitch is deceptively simple: we have the world's fastest Antibiotic Susceptibility Testing (AST) platform. But the real story isn't just about speed—it's about how a lean Swiss startup is tackling antimicrobial resistance with physics, not biology.

"Resistell isn't just testing antibiotics—they're compressing days of lab work into hours of nanomotion data."

The company's LinkedIn and Facebook presence shows a classic B2B medical device playbook: educational content, conference announcements, and partnership announcements. With 27 employees and $6.8M in revenue, they're at that critical inflection point—proven technology, early commercial traction, but facing the 'valley of death' between pilot programs and scaled deployment. Their funding status is notably absent from public data, which either means they're bootstrapped, privately funded, or intentionally flying under the radar from competitors.

• Ultra-rapid AST (4 hours vs. 48-72 hours standard)
• Nanomotion technology detects bacterial movement, not just growth
• Hyper-local marketing strategy focused on Swiss healthcare system
• Revenue-generating with $6.8M but minimal digital footprint
• Targeting antimicrobial resistance—a $100 trillion global economic threat